1. Measures to eradicate multidrug-resistant organism outbreaks: how much do they cost? 
G. Birgand, L.S.P. Moore, C. Bourigault, V. Vella, D. Lepelletier, A.H. Holmes, J.-C. Lucet 
Clinical Microbiology and Infection 
Volume 22, Issue 2, Pages 162.e1-162.e9 (February 2016)
DOI: /j.cmi
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Flowchart of the search strategy. CPE, carbapenemase-producing Enterobacteriacae; CRAB, carbapenemase-resistant Acinetobacter baumannii; GRE, glycopeptide-resistant enterococci; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus.
Clinical Microbiology and Infection  , 162.e1-162.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Description of infection control (IC) measures used and costs estimated in the included studies. Grey boxes: IC measures implemented in the study, and costs detailed by category in the article. Amber and green boxes: costs represented by boxes with the same colour are not detailed; an overall cumulated cost, gathering all categories in the article, is detailed.
Clinical Microbiology and Infection  , 162.e1-162.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions